ClinicalTrials.gg

Program

teropavimab

Its studies are mostly in HIV Infections, led by Gilead Sciences.

Furthest: phase 3, since Jun 26, 20264 company-led studies, 3 open or runningNext primary completion: Mar 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences43 open or runningphase 3since Jun 26, 2026Mar 19, 2021Mar 2029phase 3 · NCT07682961

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2021First study: phase 1 study in HIV-1 InfectionFirst studyNCT04811040 · 32 enrolled · United States
  2. Feb 6, 2023Phase 2 study in HIV-1 InfectionNCT05729568 · 83 enrolled · United States, Australia, Canada and more
  3. Jun 26, 20262 phase 3 studiesPhase 3 reachedNCT07683000, NCT07682961

Ahead

  1. Mar 2029Primary completion: phase 3 study in HIV-1-infectionNCT07683000
  2. Mar 2029Primary completion: phase 3 study in HIV InfectionsNCT07682961

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07683000HIV-1-infection · United States3RecruitingMar 2029590
NCT07682961HIV Infections · United States, Australia, Japan3RecruitingMar 2029590
NCT05729568HIV-1 Infection · United States, Australia, Canada and more2Active, not recruitingJul 2, 202483
NCT04811040HIV-1 Infection · United States1CompletedJun 9, 202232

How it is read

Names in the registry

  • “Teropavimab”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.